U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 8 of 8 results

Status:
Investigational

Class (Stereo):
CHEMICAL (UNKNOWN)



Otenzepad is the first competitive muscarinic M2 antagonist that is cardioselective and had been in phase III clinical trials for the treatment of arrhythmias and bradycardia. Otenzepad was originally developed by Boehringer Ingelheim Pharma KG (Boeh...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)



Lefradafiban, an orally active prodrug of fradafiban, is a novel glycoprotein (IIb/IIIa) inhibitor for the treatment of unstable angina. The pharmacokinetic and pharmacodynamic properties of lefradafiban were assessed in 130 healthy male volunteers ...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)

Conditions:

Etosalamide (O-(2-ethoxyethoxy)benzamid) is salicylamide derivative, that undervent metabolic transformation to O-carbamoylphenoxyaceticacid in human body. The physiological and toxicological properties of this compound have not been evaluated.
Status:
US Previously Marketed
First approved in 1958

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Bisacodyl is typically prescribed for relief of constipation and for the management of neurogenic bowel dysfunction as well as part of bowel preparation before medical examinations, such as for a colonoscopy. Some drugs (e.g., diuretics, angiotensin ...
Status:
Investigational

Class (Stereo):
CHEMICAL (UNKNOWN)



Otenzepad is the first competitive muscarinic M2 antagonist that is cardioselective and had been in phase III clinical trials for the treatment of arrhythmias and bradycardia. Otenzepad was originally developed by Boehringer Ingelheim Pharma KG (Boeh...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)



Lefradafiban, an orally active prodrug of fradafiban, is a novel glycoprotein (IIb/IIIa) inhibitor for the treatment of unstable angina. The pharmacokinetic and pharmacodynamic properties of lefradafiban were assessed in 130 healthy male volunteers ...
Status:
Investigational

Class (Stereo):
CHEMICAL (RACEMIC)



Otenzepad is the first competitive muscarinic M2 antagonist that is cardioselective and had been in phase III clinical trials for the treatment of arrhythmias and bradycardia. Otenzepad was originally developed by Boehringer Ingelheim Pharma KG (Boeh...
Status:
US Previously Marketed
First approved in 1958

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Bisacodyl is typically prescribed for relief of constipation and for the management of neurogenic bowel dysfunction as well as part of bowel preparation before medical examinations, such as for a colonoscopy. Some drugs (e.g., diuretics, angiotensin ...